Abstract
DPP-4i are incretin-based anti-diabetes drugs which have been introduced recently. It is concerned that, however, that DPP-4i might cause pancreatic cancer or pancreatitis due to the pleiotropic effects for the exocrine pancreas. In this study, the association between pancreatic cancer and DPP-4i was investigated based on CDM, an emerging tool for real world data (RWD) analysis. The electronic hospital record (EHR) of diabetic patients treated with Dipeptidyl peptidase 4 inhibitors (DPP-4i) from 2006 to 2019 was pooled into common data model (CDM) and compared with those with sodium-glucose cotransporter inhibitors (SGLT)-2i as the control. The enrollment assessment window was considered 6 months. The blackout and washout periods were defined as 2 and 56 days, respectively. Each cohort of DPP-4i and SGLT-2i consisting of 141,387 and 13,378 patients was formed. Pancreatic cancer was identified in 2,803 (2.14%) patients from the DPP-4i cohort and 129 (1.07%) from the SGLT-2i cohort, which showed statistical difference (P < 0.0001). The odds ratio was 2.02 (95% confidential interval: 1.69-2.41) with fixed and random effect models. The study suggests there is increased risk of pancreatic cancer for patients treated with DPP-4i.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
